Core Viewpoint - Compass Diversified (NYSE: CODI) has warned investors not to rely on its previously issued financial statements for fiscal years ending December 31, 2022 and 2023 due to expanded accounting irregularities [1][5]. Group 1: Financial Irregularities - The company disclosed that accounting irregularities at its subsidiary, Lugano Holding, affected financial statements for fiscal years 2022, 2023, and 2024, necessitating restatements [4][5]. - The irregularities include violations of applicable accounting rules and industry practices concerning financing, accounting, and inventory procedures [9]. Group 2: Legal Actions - Following the announcement of accounting issues, Compass Diversified is facing multiple class-action lawsuits, with the lead plaintiff's deadline set for July 8, 2025 [3][4]. - The amended complaint in the case Moreno v. Compass Group Diversified Holdings LLC seeks to represent investors who purchased shares from February 24, 2022, to May 7, 2025 [3][4]. Group 3: Market Reaction - The market reacted severely to the news, with Compass Diversified's stock price dropping by over 62% following the disclosure of the accounting irregularities [7]. Group 4: Investigations - Hagens Berman, a national investor rights law firm, is conducting an investigation into potential securities violations by Compass Diversified [8][10]. - The firm's investigation highlights a lack of effective internal controls over financial reporting, leading to materially misstated financial results [9].

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the proposed sale of Sage Therapeutics, Inc. to Supernus Pharmaceuticals, Inc., focusing on the financial implications for current shareholders and the contingent value rights associated with the transaction [1]. Company Overview - Sage Therapeutics, Inc. is involved in a proposed sale to Supernus Pharmaceuticals, Inc. Current shareholders are set to receive $8.50 per share in cash, along with a non-tradable contingent value right worth up to $3.50 per share [1]. Financial Details - The contingent value right includes three potential cash payments: - $0.50 upon the first commercial sale of the drug Zurzuvae in Japan by June 30, 2026 - $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. by December 31, 2028 - $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. by December 31, 2030 [1]. Legal Context - Monteverde & Associates PC is recognized as a top firm in securities class action services and has a successful track record in recovering money for shareholders [1].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Reddit, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is from October 29, 2024, to May 20, 2025, and the lead plaintiff deadline is August 18, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its success in this area [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding user engagement and advertising revenues due to changes in Google Search's algorithm [4]. - It is claimed that these algorithm changes led to a significant reduction in traffic to Reddit, which the defendants were aware of but failed to disclose [4]. - The lawsuit asserts that the true impact of these changes was not communicated to investors, resulting in damages when the information became public [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased DoubleVerify common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

🗞️ Trump/Musk feud escalates, causing $TSLA to tumble.🗞️ Senator Lummis seeks to waive US taxes on small crypto transactions🗞️ Bitcoin records monthly high, but Euro steals the show.@jennsanasie hosts "CoinDesk Daily." 🔗👇Thank you to @bahamut_chain 🤝 for being a sponsor of CoinDesk Media Network. ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false a ...

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Petco’s business, operations, and prospects, including allegations that: (i) Petco’s pandemic-related tailwinds were unsustainable, as was its business model of selling primarily p ...

YZi Labs-backed perps DEX Vooi launches V2 mainnet, enabling cross-chain transactions via chain abstraction https://t.co/r0bBJAjekS ...